Lilly vs Pfizer: Obesity Race Reaches Market Highs
Lilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...
Uncover the best high cash back cards that charge no annual fees. Maximize your rewards while keeping your costs down.
28,270 articlesLilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...
Meta’s AI model outlines multiple XRP price paths for 2026, showing a base target and upside scenarios as ETF demand ...
As July 18, 2026 approaches, the GENIUS Act deadline accelerates rulemaking for stablecoin issuers. Regulators from T...
When Maddox Jolie changes how his name appears in a movie credit, it isn’t just showbiz—it tugs at contracts, taxes, ...
ASML expands beyond its EUV core with a strategic foray into advanced packaging. The move comes as TSMC leads the CoW...
The SEC is moving to settle Justin Sun's case with a $10 million penalty, a move that could reshape crypto enforcemen...
host mike rowe slams the college-first script as earnings in the trades rise, with data center electricians pulling i...
When two comedy heavyweights end a years-long feud on a live Netflix roast, it becomes more than a moment of laughter...
The Roundhill Memory ETF DRAM has surged in 2026, roughly doubling and delivering a year-to-date gain near 100% as AI...
RAD Intel debuts a Regulation A+ offering at $0.91 per share, pitching an AI-driven marketing engine as the next oppo...
Goldman Sachs and MORGAN STANLEY are jockeying for the lead left role in a pair of AI IPOs, a $7 billion opportunity ...
A senior AI executive is leaving Meta Platforms, adding to tech worries. On Wednesday, the stock fell more than 5%, p...